Anavex life sciences to present at the b. riley securities' virtual neuroscience conference

New york, april 26, 2021 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) disorders, today announced that christopher u. missling, phd, president and chief executive officer of anavex, will present at the b. riley securities' virtual neuroscience conference on wednesday, april 28, 2021 at 12:00 p.m. edt.
AVXL Ratings Summary
AVXL Quant Ranking